Department of Neurology, University of Virginia, PO Box 800394, Charlottesville, VA 22908, USA.
Mult Scler Relat Disord. 2016 Sep;9:47-9. doi: 10.1016/j.msard.2016.06.007. Epub 2016 Jun 23.
Fingolimod (Gilenya, Novartis) is an oral sphingosine-1-phosphate analogue used in the treatment of relapsing multiple sclerosis (MS). Fingolimod treatment is associated with relative lymphopenia and was associated with an increased risk of herpes infection in clinical trials. In the post-marketing setting, fingolimod has been associated with several cases of cryptococcal meningitis, recently prompting an update to its prescribing information. To date, all cases have been associated with active treatment with fingolimod. In this report, we describe the first case of cryptococcal meningitis diagnosed after fingolimod discontinuation.
芬戈莫德（Gilenya，诺华）是一种用于治疗复发型多发性硬化症（MS）的口服鞘氨醇-1-磷酸类似物。芬戈莫德治疗与相对淋巴细胞减少有关，并与临床试验中疱疹感染风险增加相关。在上市后环境中，芬戈莫德与几例隐球菌性脑膜炎有关，最近促使其用药信息更新。迄今为止，所有病例均与芬戈莫德的积极治疗有关。在本报告中，我们描述了首例在停用芬戈莫德后诊断出的隐球菌性脑膜炎病例。
